Response to "Conditioning with melphalan (Mel) 200 mg/m2 and subsequent autologous stem cell transplantation improves progression free survival and overall survival in elderly multiple myeloma patients compared to standard of care"

Eur J Haematol. 2023 Feb;110(2):221. doi: 10.1111/ejh.13888. Epub 2022 Nov 8.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Aged
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Melphalan
  • Multiple Myeloma* / therapy
  • Progression-Free Survival
  • Standard of Care
  • Transplantation Conditioning
  • Transplantation, Autologous

Substances

  • Melphalan